Noui N, Zogheib E, Walczak K, Werbrouck A, Amar A Ben, Dupont H, Caus T, Remadi J P
Anesthesiology Unit, South Hospital, Amiens, France.
Perfusion. 2012 May;27(3):214-20. doi: 10.1177/0267659112436632. Epub 2012 Feb 2.
The objective of our study was to compare the standard protocol of anticoagulation to the Hepcon/HMS.
This study included forty-four patients who underwent coronary bypass grafting surgery (CABG), or biological aortic valve replacement (AVR). Unfractionated heparin (UH) was used for patients who underwent operations in the control group (n = 22) (300U/Kg of UH with a goal of an ACT of 400s). The heparin was antagonized dose/dose by protamine. For the patients who underwent operations in the HMS group (n = 22), the heparin and protamine doses were assessed by the Hepcon/HMS device.
The sex ratio amounted to 1.93 (29 men and 15 women) and the mean age was 70 ± 11 years. The patients in the HMS group had a chest closure time that was significantly shorter than patients in the control group. The times were, respectively, 42 ± 15 minutes and 68 ± 27 minutes (p = 0.001). The protamine/heparin ratio was significantly lower in the HMS group (0.62 ± 0.13 vs. 1 ± 0.11) (p = 0.0001). The postoperative bleeding amounted to 804 ± 729 ml in the HMS group versus 1416 ± 1103 in the control group (p = 0.016). In multivariate linear regression analysis, only two independent factors were significantly associated with bleeding: the Hepcon/HMS (OR = 0.1-p = 0.03) and the preoperative hemoglobin rate (OR = 1.4 - p = 0.05). Postoperatively, within 72 hours, the red blood cell transfusion was 1.04 ± 1.5 units for the HMS group and 2.1 ± 1.87 units for the control group (p = 0.05).
During cardiac surgery under CPB, heparin and protamine titration with the Hepcon/HMS device could predict a lower protamine dose and lower postoperative bleeding without higher thromboembolic events, and lower perioperative red blood cell transfusion with a shorter chest closure time.
本研究的目的是将抗凝标准方案与Hepcon/HMS进行比较。
本研究纳入了44例行冠状动脉搭桥术(CABG)或生物主动脉瓣置换术(AVR)的患者。对照组(n = 22)中接受手术的患者使用普通肝素(UH)(300U/Kg的UH,目标活化凝血时间(ACT)为400秒)。肝素通过鱼精蛋白按剂量进行拮抗。对于在HMS组(n = 22)中接受手术的患者,肝素和鱼精蛋白的剂量通过Hepcon/HMS设备进行评估。
性别比为1.93(29名男性和15名女性),平均年龄为70±11岁。HMS组患者的关胸时间明显短于对照组患者。时间分别为42±15分钟和(对照组)68±27分钟(p = 0.001)。HMS组的鱼精蛋白/肝素比值明显更低(0.62±0.13对1±0.11)(p = 0.0001)。HMS组术后出血量为804±729毫升,而对照组为1416±1103毫升(p = 0.016)。在多变量线性回归分析中,只有两个独立因素与出血显著相关:Hepcon/HMS(比值比(OR)= 0.1 - p = 0.03)和术前血红蛋白率(OR = 1.4 - p = 0.05)。术后72小时内,HMS组红细胞输注量为1.04±1.5单位,对照组为2.1±1.87单位(p = 0.05)。
在体外循环心脏手术期间,使用Hepcon/HMS设备进行肝素和鱼精蛋白滴定可预测较低的鱼精蛋白剂量和较低的术后出血量,且不会增加血栓栓塞事件,同时围手术期红细胞输注量较低且关胸时间较短。